The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars
- Authors: Mazzoni D.; Vener C.; Mazzocco K.; Monzani D.; Pravettoni G.
- Publication year: 2021
- Type: Articolo in rivista
- Key words: adherence; nocebo effect; oncology; rheumatology; shared decision-making
- OA Link: http://hdl.handle.net/10447/543288
Abstract
Biological products are therapeutic agents produced using a living system or organism. In many cases, access to these products is limited due to their expensive cost (Chow et al., 2011). A biosimilar is a biological product that is highly similar (not identic) to, and has no clinically meaningful differences from, an existing reference biological product on the market (Desai et al., 2020). “Non-medical” switching is the switching of a patient's medicine for reasons other than the patient's health and safety, like the reduction of costs (Dolinar et al., 2019).